A bill to provide for the expedited development and evaluation of drugs designated as breakthrough drugs.
The bill’s titles are written by its sponsor.
Sponsor and status
Sponsor. Senator for Colorado. Democrat.
Last Updated: Mar 26, 2012
Length: 8 pages
Mar 26, 2012
112th Congress, 2011–2013
Died in a previous Congress
This bill was introduced on March 26, 2012, in a previous session of Congress, but was not enacted.
Mar 26, 2012
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.
S. 2236 (112th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
This bill was introduced in the 112th Congress, which met from Jan 5, 2011 to Jan 3, 2013. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
GovTrack.us. (2018). S. 2236 — 112th Congress: Advancing Breakthrough Therapies for Patients Act of 2012. Retrieved from https://www.govtrack.us/congress/bills/112/s2236
“S. 2236 — 112th Congress: Advancing Breakthrough Therapies for Patients Act of 2012.” www.GovTrack.us. 2012. November 19, 2018 <https://www.govtrack.us/congress/bills/112/s2236>
Advancing Breakthrough Therapies for Patients Act of 2012, S. 2236, 112th Cong..
|title=S. 2236 (112th)
|accessdate=November 19, 2018
|author=112th Congress (2012)
|date=March 26, 2012
|quote=Advancing Breakthrough Therapies for Patients Act of 2012
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.